BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Quarterly Reports

Q1 2019 Report

Wednesday, 8 MayFelix Konferansesenter, Bryggetorget 3, 0125 Oslo

The webcast will be streamed LIVE and the recording will be available after LIVE session is finished.

Link to live webcast

Corporate Presentation

H.C. Wainwright Global Life Sciences Conference

Apr 9th 2019

April 9th: London, UK

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

BerGenBio completes recruitment into second stage of Phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC

BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2019

More News

Scientific Presentations

AACR, Ramkumar et al

Mar 29 - Apr 3, 2019Atlanta, Georgia

Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress

Read More

Annual Report 2018

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference 2019, April 7-9

37th Annual J.P. Morgan Healthcare Conference 2019, January 7-10

DNB Healthcare Conference 2018, December 12

60th ASH Annual Meeting & Exposition 2018, December 1-4

Jefferies 2018 London Healthcare Conference, November 14-15

More Events